for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Repligen Corporation

RGEN.OQ

Latest Trade

81.79USD

Change

-0.62(-0.75%)

Volume

3,641,738

Today's Range

80.95

 - 

83.54

52 Week Range

48.26

 - 

99.21

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
82.41
Open
82.32
Volume
3,641,738
3M AVG Volume
15.90
Today's High
83.54
Today's Low
80.95
52 Week High
99.21
52 Week Low
48.26
Shares Out (MIL)
51.53
Market Cap (MIL)
4,214.70
Forward P/E
84.32
Dividend (Yield %)
--

Next Event

Q3 2019 Repligen Corp Earnings Release

Latest Developments

More

Repligen Reports Second Quarter 2019 Financial Results And Updates Full Year 2019 Financial Guidance

Repligen Announces Pricing Of Public Offerings Of $120 Mln Of Stock, $250 Mln Of 0.375% Convertible Senior Notes Due 2024

Repligen Expects Total Revenue For Quarter Ended June 30 Will Be Between $70 Mln And $71 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company's portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

Industry

Biotechnology & Drugs

Contact Info

41 Seyon St Bldg 1 Ste 100

+1.781.4499560

https://www.repligen.com/

Executive Leadership

Karen A. Dawes

Independent Chairperson of the Board

Anthony John Hunt

President, Chief Executive Officer, Director

Jon K. Snodgres

Chief Financial Officer

Ralf Kuriyel

Senior Vice President - Research and Development

Nicolas M. Barthelemy

Independent Director

Key Stats

1.75 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.2K

2019(E)

0.3K
EPS (USD)

2016

0.440

2017

0.690

2018

0.730

2019(E)

0.970
Price To Earnings (TTM)
144.78
Price To Sales (TTM)
18.10
Price To Book (MRQ)
4.47
Price To Cash Flow (TTM)
96.76
Total Debt To Equity (MRQ)
12.03
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
3.43
Return on Equity (TTM)
2.93

Latest News

BRIEF-Repligen Reports Q1 Adjusted Non-GAAP Earnings Per Share Of $0.17

* Q1 EARNINGS PER SHARE VIEW $0.15 -- THOMSON REUTERS I/B/E/S

BRIEF-Repligen Reports Q4 GAAP Earnings Per Share $0.27

* REPLIGEN REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS, PROVIDES GUIDANCE FOR 2018

BRIEF-Repligen reports Q3 adjusted non-GAAP earnings per share $0.15

* Q3 earnings per share view $0.11 -- Thomson Reuters I/B/E/S

BRIEF-Repligen extends long term supply agreement with Purolite for Protein A ligands

* Repligen extends long term supply agreement with Purolite for Protein A ligands

BRIEF-Roy Eddleman reports 11 pct passive stake in Repligen

* Roy T. Eddleman reports 11.0 percent passive stake in Repligen Corp as of August 1, 2017 - sec filing Source text: (http://bit.ly/2vRsiEb) Further company coverage:

BRIEF-Repligen prices public offering of shares of common stock

* Repligen Corporation prices public offering of shares of common stock

BRIEF-REPLIGEN CORP ANNOUNCES PROPOSED PUBLIC OFFERING OF SHARES OF COMMON STOCK

* REPLIGEN CORPORATION ANNOUNCES PROPOSED PUBLIC OFFERING OF SHARES OF COMMON STOCK

BRIEF-Repligen and Spectrum to join forces

* Repligen Corp - deal expected to be accretive to repligen earnings per share in fiscal 2018

BRIEF-Repligen posts Q4 adj. earnings per share $0.08

* Repligen reports fourth quarter 2016 financial results, provides guidance for 2017

BRIEF-Repligen Q3 non-gaap EPS $0.08

* Revenue for q3 of 2016 increased to $24.7 million compared to $19.8 million for q3 of 2015

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up